SBI Holdings, Inc.
SBI Pharmaceuticals Co., Ltd.

We  are  pleased   to  inform  you  that  SBI  Pharmaceuticals   Co.,  Ltd.  (Head   office:  Minato-ku,   Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (5-ALA) (*), announces that it has obtained a business license for selling and renting highly controlled medical devices from the Tokyo Metropolitan Government.

Having received this business license for selling and renting highly controlled medical devices, SBI Pharmaceuticals can sell and rent highly controlled medical devices, controlled medical devices, and general medical devices classified as controlled medical devices requiring special maintenance.

Given this authorization on top of the licenses it already holds for manufacturing and sales of pharmaceuticals and cosmetics, SBI Pharmaceuticals is in a position to more aggressively pursue its business activities in the fields of medicine and healthcare.

We will continue to strive toward providing pharmaceutical products as well as enhanced services with medical devices.

The details of the business license granted for selling and renting highly controlled medical devices are as provided below.

Business of selling and renting highly controlled medical devices

Authorization number: 4501031300031
Effective period: 12 September 2013 to 11 September 2019
Name of business office: SBI Pharmaceuticals Co., Ltd.
Location of business office: Izumi Garden Tower 20F, 1-6-1 Roppongi, Minato-ku, Tokyo

*1 5-aminolevulinic acid (5-ALA): An amino acid created in mitochondria. It is an important substance that serves as protein material related to energy production in the form of hemes and cytochromes, and its productivity is known to decrease with age. 5-ALA is contained in shochu distillation remnants, red wine and food such as radish sprouts. It is also known as a material forming chloroplasts in plants

*****************************************************************************************
For further information, please contact:
SBI Holdings, Inc.: Corporate Communications Dept., Tel: +81 3 6229 0126
SBI Pharmaceuticals Co., Ltd.: Division of Drug Development, Tel: +81 3 6229 0095

Please download PDF File